DSIP (10 mg Vial) Dosage Protocol

Plan based on an 8–12 week nightly protocol with gradual titration.

• Peptide Vials (DSIP, 10 mg each):
  • 8 weeks: approximately 1 vial required (10 mg supports ~33–100 doses at 100–300 mcg)
  • 12 weeks: approximately 2 vials required
• Insulin Syringes (30- or 50-unit recommended for small volumes):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (1 vial): 3 mL - 1 bottle required (10 mL each)
  • 12 weeks (2 vials): 6 mL - 1 bottle required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs - 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs - 2 boxes required (100 swabs each)

DSIP 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
• Typical daily range: 100–300 mcg once daily in the evening (gradual titration).
• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

DSIP dosage protocols can help promote deep, restorative delta-wave sleep and support healthy stress response. Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (9 amino acids) first isolated from rabbit brain for its ability to enhance slow-wave sleep^[1]. Research indicates DSIP may improve sleep quality, normalize sleep architecture, reduce stress-related cortisol patterns, and support mood stabilization without next-day grogginess^[2][3]. This educational protocol presents a once-daily subcutaneous evening approach using a practical dilution for clear insulin-syringe measurements.

This DSIP dosage page keeps the 10 mg vial calculations, U-100 syringe markings, reconstitution volume, and community-reported schedule together. The dosage chart above is a measurement guide for research review; it is not a clinically validated treatment schedule.

• Compound: DSIP, or delta sleep-inducing peptide, is a nine-amino-acid peptide originally characterized during animal EEG research^[12].
• Vial strength: 10 mg of lyophilized DSIP.
• Final concentration: 3.0 mL of diluent produces approximately 3.33 mg/mL.
• Measurement rule: On a U-100 syringe, 1 unit equals 0.01 mL, or approximately 33.3 mcg at this concentration.
• Evidence boundary: Published human DSIP research used intravenous administration, not the subcutaneous schedule displayed above^[3][5].

The concentration formula is vial mass divided by final liquid volume: 10 mg ÷ 3.0 mL = 3.33 mg/mL. Converting milligrams to micrograms gives 3,333 mcg/mL. Because one U-100 unit is 0.01 mL, each unit contains about 33.3 mcg.

• 100 mcg: 100 ÷ 33.3 ≈ 3 units (0.03 mL).
• 150 mcg: 150 ÷ 33.3 ≈ 4.5 units; the chart rounds to a readable syringe marking.
• 200 mcg: 200 ÷ 33.3 ≈ 6 units (0.06 mL).
• 250 mcg: 250 ÷ 33.3 ≈ 7.5 units; the chart uses the nearest practical marking.
• 300 mcg: 300 ÷ 33.3 ≈ 9 units (0.09 mL).

These are arithmetic conversions, not dose recommendations. Always read the mass and volume together: syringe units measure liquid volume and are not peptide international units.

Vial strength changes concentration, syringe markings, and the number of calculations available from one container. It does not establish a different biological DSIP dosage range. A 10 mg vial and a 5 mg vial contain the same peptide; they require separate pages because a different vial mass can produce different U-100 measurements after reconstitution.

• Family role: This 10 mg page is the broad DSIP dosage resource for the family.
• Strength-specific intent: Readers looking for DSIP 10 mg reconstitution can use the concentration and unit conversions above. The supplier card and vial image use the approved Pure Lab Peptides product record for provenance^[15].
• Other strength: The DSIP 5 mg dosage protocol retains its own vial-specific calculations.

The human literature is small, old, and methodologically mixed. Early controlled work evaluated sleep or daytime performance in people with chronic insomnia, but sample sizes were limited and the administration route was intravenous. A placebo-controlled, double-blind study in 14 people reported improvements in sleep and daytime function after seven successive nights^[3]. An earlier clinical summary also described sleep changes after injections and suggested that timing and repeated administration could influence the result^[4].

A later double-blind study in 16 people with chronic insomnia found higher sleep efficiency and shorter sleep latency for some objective measures, yet the authors characterized the effects as weak, found no improvement in subjective sleep quality, and concluded that short-term DSIP was unlikely to provide major therapeutic benefit^[5]. The findings therefore do not support describing any DSIP peptide dosage as proven insomnia treatment.

Modern interpretation is also limited by uncertainty about DSIP biology. A later review described the proposed connection between DSIP and sleep as poorly documented because the endogenous peptide system, gene, protein, and receptor were not clearly established^[11]. The result is an evidence record with interesting signals, contradictory findings, and no validated subcutaneous DSIP dosage protocol.

Searches for a DSIP dosage for sleep often compress several different experiments into a single claim. The original research program included animal EEG experiments, small human sleep studies, and later reviews. Those sources are not interchangeable. The first structural research identified the nonapeptide sequence and reported delta- and spindle-EEG activity after direct brain administration in rabbits^[12]. That experiment established a research lead, not a human dosing standard.

Small human studies later reported changes in sleep latency, sleep efficiency, or daytime alertness^[3][4]. Other controlled work found effects too weak or inconsistent to support a major therapeutic benefit^[5]. Reviews consequently describe DSIP as a broad neuromodulatory research compound rather than a settled sleep medicine^[2][11].

For that reason, sleep-related claims on this page are evidence summaries. They do not establish that the community-reported subcutaneous schedule in the primary dosage chart reproduces the results of historical intravenous trials.

DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Early literature associated it with delta-rhythm EEG activity, but later work broadened the proposed effects to stress signaling, endocrine responses, pain, withdrawal, and other neurophysiological systems^[1][2]. That range of reported activity is one reason the mechanism remains unresolved.

In a randomized crossover study of healthy men, an intravenous DSIP exposure reduced ACTH-like immunoreactivity for several hours without changing plasma or urinary cortisol^[13]. During isoflurane anesthesia, a small randomized study found that intravenous DSIP increased heart rate, reduced heart-rate variability, decreased delta rhythm, and lightened measured anesthesia depth rather than deepening it^[14]. Those results caution against presenting DSIP as a simple sedative or assuming that every change in delta activity means better sleep.

Preclinical formulation research has explored ways to improve peptide delivery across the blood-brain barrier^[7]. However, delivery experiments and animal models cannot define a safe or effective human DSIP peptide dosage.

Route is a central limitation when comparing the literature with online DSIP dosage charts. Historical human sleep studies administered DSIP intravenously, commonly by infusion or injection in a controlled research setting^[3][5]. The primary chart on this page records a community-reported subcutaneous approach and converts its amounts into syringe markings. It does not claim that subcutaneous pharmacokinetics, bioavailability, or outcomes match the published intravenous research.

Separate studies also examined DSIP in chronic pain^[8] and withdrawal syndromes^[9]. These older reports involved different populations and research questions, so they cannot be used to validate a sleep protocol. They remain useful as historical context for the breadth of DSIP investigation.

When comparing any DSIP dosage protocol, check five details: vial strength, final volume, concentration, route, and whether the amount is per administration or a daily total. If one of those details is missing, the protocol cannot be translated reliably into U-100 syringe units.

DSIP is also known as emideltide. It is not a component of an FDA-approved drug. FDA materials evaluating emideltide-related bulk substances identify limited safety information for proposed subcutaneous administration and potential concerns involving immunogenicity, peptide-related impurities, and active-ingredient characterization^[16].

• Published human evidence is limited to small studies and does not establish long-term safety.
• Results from intravenous research cannot be assumed to apply to subcutaneous administration.
• Potential interactions with sedatives, sleep medicines, alcohol, or other central nervous system agents have not been adequately characterized.
• Changes in heart rate and heart-rate variability observed during anesthesia research show that DSIP should not be described as physiologically inactive^[14].
• Headache, nausea, dizziness, drowsiness, unexpected alertness, or injection-site reactions should be treated as safety signals rather than proof that a protocol is working.

This information is for educational and research review. It is not medical advice and does not recommend human use.

The four reconstitution checks in the dosage chart provide the page’s primary preparation sequence. Use aseptic technique, add the specified 3.0 mL volume slowly, avoid shaking, label the vial, and refrigerate the reconstituted solution at 2–8 °C (35.6–46.4 °F). Protect the vial from light and avoid repeated freeze-thaw cycles.

The final concentration depends on the final liquid volume, not merely the amount of water initially drawn. If liquid is lost, the stopper leaks, the solution becomes cloudy, particles appear, or the vial’s identity or storage history is uncertain, do not rely on the calculation table. Product-specific handling and discard instructions take precedence over generalized peptide storage guidance.

The chart’s smallest amounts occupy only a few U-100 syringe units. A 30-unit or 50-unit insulin syringe may make small markings easier to read, but the printed graduation pattern must still be verified. One U-100 unit represents 0.01 mL of liquid; it does not indicate one microgram or one international unit of DSIP.

General subcutaneous technique resources recommend clean preparation, a new sterile syringe for each administration, appropriate site selection, and systematic site rotation^[6][10]. CDC administration guidance, an NCBI clinical-skills reference, and a peer-reviewed review of the subcutaneous route provide additional technique and route context^[17][18][19]. These references explain injection technique only. They do not validate the peptide, route, or schedule shown on this research page.

How many U-100 units are in a 100 mcg DSIP calculation?

With a 10 mg vial reconstituted to 3.0 mL, the concentration is about 3.33 mg/mL and each U-100 unit contains about 33.3 mcg. A 100 mcg calculation is therefore approximately 3 units, or 0.03 mL.

Does a 10 mg vial require a higher DSIP dosage than a 5 mg vial?

No. Vial strength changes concentration, vial yield, and syringe-unit math. It does not by itself define a different research amount. The 5 mg and 10 mg pages are separated so each strength can show its own preparation and measurement calculations without ambiguity.

Is the DSIP dosage chart based on a clinical sleep trial?

No. The primary chart records a community-reported subcutaneous schedule for measurement context. Published human sleep studies used intravenous DSIP, and the findings were mixed^[3][5].

Is DSIP an FDA-approved insomnia medicine?

No. FDA materials state that emideltide is not a component of an FDA-approved drug, and FDA has identified insufficient safety information for proposed subcutaneous administration^[16].

Why are the reference findings contradictory?

The studies were small, used different populations and designs, and did not establish a modern dose-response program. Some reported sleep-related signals, while later controlled work found weak or clinically limited effects. A later review concluded that DSIP’s biological role and sleep connection remained unresolved^[11].

This page explains concentration, volume, and syringe-unit arithmetic for a research vial. It does not establish a standard of care, prove safety or efficacy, or recommend administering DSIP to a person.

• 1
  European Journal of Anaesthesiology - Delta sleep-inducing peptide: discovery, structure, and pharmacological overview

  View Source
• 2
  Neuroscience & Biobehavioral Reviews (PubMed) - Delta-sleep-inducing peptide (DSIP): a review of sleep-promoting and neuromodulatory research

  View Source
• 3
  European Neurology (PubMed) - Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia

  View Source
• 4
  European Neurology (PubMed) - DSIP in insomnia: timing and frequency of administration in clinical trials

  View Source
• 5
  Neuropsychobiology (PubMed) - Effects of DSIP on chronic insomnia in a double-blind matched-pairs study

  View Source
• 6
  MedlinePlus - Subcutaneous injection technique, site selection, and preparation

  View Source
• 7
  Frontiers in Pharmacology - DSIP fusion-peptide delivery and blood-brain-barrier research in insomnia models

  View Source
• 8
  European Neurology (PubMed) - Therapeutic effects of DSIP in patients with chronic pain episodes

  View Source
• 9
  European Neurology (PubMed) - DSIP research in withdrawal syndromes from alcohol and opiates

  View Source
• 10
  Johns Hopkins Arthritis Center - How to give a subcutaneous injection and rotate sites

  View Source
• 11
  Journal of Neurochemistry (PubMed) - Delta sleep-inducing peptide: a still unresolved riddle

  View Source
• 12
  Proceedings of the National Academy of Sciences (PubMed) - Characterization of delta EEG sleep-inducing peptide and its nine-amino-acid sequence

  View Source
• 13
  Psychoneuroendocrinology (PubMed) - ACTH-like immunoreactivity after intravenous DSIP in a randomized crossover study

  View Source
• 14
  European Journal of Anaesthesiology (PubMed) - DSIP effects on EEG, bispectral index, and heart-rate variability during anesthesia

  View Source
• 15
  Pure Lab Peptides - DSIP 10 mg product page for vial provenance and batch documentation

  View Source
• 16
  U.S. Food and Drug Administration - FDA evaluation of emideltide-related bulk drug substances and safety limitations

  View Source
• 17
  Centers for Disease Control and Prevention - Administration guidance for the subcutaneous route

  View Source
• 18
  NCBI Bookshelf - Clinical best practices for injection preparation and administration

  View Source
• 19
  Peer-reviewed subcutaneous injection review (PMC) - Pharmacologic and practical considerations for the subcutaneous route

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.